Conference Coverage

Divergent findings with paclitaxel and nab-paclitaxel in TNBC


 

FROM ESMO 2020

Results of IMpassion130

Presenting the final OS analysis from IMpassion130, Dr. Emens noted that the study’s findings have led to recommendations for atezolizumab plus nab-paclitaxel as first-line treatment of PD-L1-positive TNBC in international guidelines.

The median OS in the ITT population was 18.7 months in the placebo arm and 21.0 months in the atezolizumab arm (stratified HR, 0.87, P = .077). The 3-year OS rates were 25% and 28%, respectively.

The median OS in the PD-L1-positive population was 17.9 months in the placebo arm and 25.4 months in the atezolizumab arm (HR, 0.67). The 3-year OS rates were 22% and 36%, respectively.

A P value is not available for the between-arm OS comparison in the PD-L1-positive population. OS was not formally tested in this group because the OS boundary for statistical significance was not crossed in the ITT population. However, Dr. Emens said there was a “clinically meaningful” OS benefit observed with atezolizumab in the PD-L1-positive patients.

Treatment withdrawals caused by adverse events were more common in the atezolizumab arm (19% vs. 8%). The most common of these was neuropathy, Dr. Emens said. However, she noted that atezolizumab-related adverse events were generally low grade and easily managed.

“These results support a positive benefit-risk profile for atezolizumab plus nab-paclitaxel as first-line therapy in patients with PD-L1-positive metastatic triple-negative breast cancer,” Dr. Emens concluded.

Both studies were funded by F. Hoffman–La Roche. Dr. Miles, Dr. Emens, and Dr. Carey disclosed financial relationships with Roche and other companies.

SOURCES: Miles D et al. ESMO 2020, Abstract LBA15; Emens LA et al. ESMO 2020, Abstract LBA16.

Pages

Recommended Reading

Shorter-duration trastuzumab noninferior in early breast cancer
MDedge Hematology and Oncology
COVID-19 changed early breast cancer management
MDedge Hematology and Oncology
Everolimus after palbociclib of modest value in metastatic HR+ HER2- breast cancer
MDedge Hematology and Oncology
Sarcoidosis can co-occur in older patients with breast cancer
MDedge Hematology and Oncology
Breast Cancer: 9/22/20
MDedge Hematology and Oncology
Pembrolizumab combo flops in pretreated HR-positive, ERBB2-negative breast cancer
MDedge Hematology and Oncology
First-in-class ADC ups survival in mTNBC
MDedge Hematology and Oncology
Abemaciclib cuts early recurrence in high-risk breast cancer
MDedge Hematology and Oncology
Global stomach cancer deaths decline as colorectal cancer deaths stagnate, rise
MDedge Hematology and Oncology
NCI may ‘kill’ major mammography trial, says adviser
MDedge Hematology and Oncology